Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel Transcript
Thanks, everybody, for joining the Autoimmune/Complement/Inflammation panel. With us today, we have three companies: we have Alpine Immune Sciences, we have Mitch Gold or the CEO of Alpine; we have Noreen Henig from Kezar Life Sciences; and we have Jonathan Zalevsky from Nektar Therapeutics. Thanks for our panelists for joining.
Questions & Answers
We're going to start our discussion with some thematic questions, and then we're going to dive into a company-specific question. So in thematic questions, according to our consultants and experts in the field, some drug failures, certainly in autoimmune conditions may not be primarily due to efficacy, but also due to complex scoring system and complex endpoints being used. What steps have you taken to get past some of these challenges? And how do you think the FDA is going to respond to some of these potential changes in endpoints?
I guess, why don't we just start out with Mitch, and we're going to go progressively disorder.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
